

L.N. 42 of 2018

**Pharmacy and Poisons (Amendment) (No. 2)
Regulation 2018**

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Food and Health)

1. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 2, 3 and 4.

2. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)

(1) Schedule 1, Division A, before item “Basiliximab; its salts”—

Add

“Baricitinib; its salts”.

(2) Schedule 1, Division A, after item “Cabergoline; its salts”—

Add

“Cabozantinib; its salts”.

(3) Schedule 1, Division A, after item “Etanercept”—

Add

“Etelcalcetide; its salts”.

(4) Schedule 1, Division A, after item “Gimeracil; its salts”—

Add

“Glecaprevir; its salts”.

- (5) Schedule 1, Division A, item “Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin”, after sub-item “Cimetidine”—

Add

“Deoxycholic acid”.

- (6) Schedule 1, Division A, before item “Picrotoxin”—

Add

“Pibrentasvir; its salts”.

3. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)

- (1) Schedule 3, Division A, before item “Basiliximab; its salts”—

Add

“Baricitinib; its salts”.

- (2) Schedule 3, Division A, after item “Cabergoline; its salts”—

Add

“Cabozantinib; its salts”.

- (3) Schedule 3, Division A, after item “Etanercept”—

Add

“Etelcalcetide; its salts”.

- (4) Schedule 3, Division A, after item “Gimeracil; its salts”—

Add

“Glecaprevir; its salts”.

- (5) Schedule 3, Division A, item “Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin”, after sub-item “Cimetidine”—

Add

“Deoxycholic acid”.

- (6) Schedule 3, Division A, before item “Picrotoxin”—

Add

“Pibrentasvir; its salts”.

4. Schedule 10 amended (Poisons List)

- (1) Schedule 10, section 2, Table, Part 1, Division A, before item “Basiliximab; its salts”—

Add

“Baricitinib; its salts”.

- (2) Schedule 10, section 2, Table, Part 1, Division A, after item “Cabergoline; its salts”—

Add

“Cabozantinib; its salts”.

- (3) Schedule 10, section 2, Table, Part 1, Division A, after item “Etanercept”—

Add

“Etelcalcetide; its salts”.

- (4) Schedule 10, section 2, Table, Part 1, Division A, after item “Gimeracil; its salts”—

Add

“Glecaprevir; its salts”.

- (5) Schedule 10, section 2, Table, Part 1, Division A, item “Pharmaceutical products for human parenteral

administration containing the following or their salts, as active ingredients, except in mixture with insulin”, after sub-item “Cimetidine”—

Add

“Deoxycholic acid”.

- (6) Schedule 10, section 2, Table, Part 1, Division A, before item “Picric acid”—

Add

“Pibrentasvir; its salts”.

Dr. Constance CHAN
Chairman,
Pharmacy and Poisons Board

7 March 2018

Explanatory Note

This Regulation amends the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) to add 5 items and 1 sub-item to—

- (a) Division A of Schedule 1;
- (b) Division A of Schedule 3; and
- (c) Division A of Part 1 of the Poisons List set out in Schedule 10.

2. The amendments relate to requirements concerning sale, supply, labelling and storage. Main effects of the amendments include—

- (a) that the sale, by retail, of substances newly specified—
 - (i) may only be effected on registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist; and
 - (ii) may only be effected on and in accordance with a prescription by a registered medical practitioner, registered dentist or registered veterinary surgeon; and
- (b) that the substances, if stored in retail premises, must be stored in a part of the premises to which customers are not permitted access.